Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
273
resultados
Última actualización
06/05/2026 [08:15:00]
Resumen de: WO2024088788A1
The present invention concerns the diagnosis and assessment of juvenile myelomonocytic leukemia (JMML). In particular, it relates to a method of diagnosing JMML in a subject, the method comprising a) determining the amount of at least one biomarker present on or in hematopoietic stem and progenitor cells (HSPCs) in a biological sample, said at least one biomarker being selected from each of i) group I consisting of: CD52, RAMP1, LTB, LST1, JAML, IFITM3, CD7, CD69, CD 164, CD74, TNF, TFPI, DLK1, CD82, IGHM, CALCRL, RALA, SLC2A5, HSPA5, HLA-DRA, RABI 1 A, SELL, VAMPS, FCMR, CLEC7A, NDFIP1, CLEC9A, HCST, LPAR6, HLA-DQA1, HLA-DRB5, and CD34, and ii) group II consisting of: IGLL1, BEST1, EREG, SLC5A3, SELK, PRRG3, NINJ1, MGST1, and HLA-G, b) comparing the determined amount of step a) to a reference, and c) diagnosing JMML based on the comparison of step b). Furthermore, the present invention relates to a method of classifying a subject suffering from JMML into a JMML low- or high-risk group. In addition, the present invention concerns use of at least one biomarker present on or in HSPCs in a biological sample for diagnosing JMML into a JMML low- or high-risk group in a subject having or having a risk of developing JMML. Furthermore, the present invention relates to a kit for diagnosing JMML in a subject or classifying a subject suffering from JMML into a JMML low- or high-risk group. Also, the present invention concerns an inhibitory agent that specifically inhibits at least one b
Resumen de: WO2026088136A1
The present disclosure provides a method of treating a neurodegenerative disease such as Alzheimer's disease in a subject. The method includes administering to the subject about 30 mg of AR1001 orally once daily, or a pharmaceutically acceptable salt thereof, and monitoring plasma phosphorylated tau 181 (pTau181) or phosphorylated tau 217 (pTau217) levels in the subject during treatment. The method may further include continuing AR1001 treatment if the subject's plasma pTau181 or pTau217 levels decrease during treatment. The subject may have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. The method may also include assessing the subject's cognitive function using one or more standardized tests during treatment. AR1001 may be administered in a pharmaceutical composition in the form of a tablet or capsule.
Resumen de: WO2026090056A1
Methods of citrullinating one or more proteins by contacting them with protein-arginine deiminase (PAD) in a reaction buffer having a concentration of free-calcium ions below 2mM and a concentration of free-bicarbonate ions above 10 mM, related protein arrays of citrullinated proteins, assay kits and related methods.
Resumen de: WO2026090007A2
In one aspect disclosed herein is a method comprising: coupling a biomolecule to a surface; detecting the biomolecule using surface-enhanced Raman spectroscopy (SERS); and based at least in part on the detecting in b), identifying the biomolecule at an accuracy of at least 75%. In another aspect disclosed herein is a method comprising: coupling an analyte on a surface; detecting the analyte using surface-enhanced Raman spectroscopy (SERS) to obtain analyte data; and identifying the analyte by applying a trained machine learning algorithm to the analyte data, wherein the trained machine learning algorithm does not comprise comparing the analyte data to a database comprising data associated with a reference molecule.
Resumen de: US20260118371A1
Disclosed herein are methods for diagnosing a subject as having a neurological disorder, such as Alzheimer's disease, using proximity-based detection assays capable of detecting complexes containing two or more synaptic proteins, such as neuronal pentraxins, from a blood, cerebrospinal fluid, or other fluid sample of the subject. Also disclosed are methods of evaluating and monitoring subjects having or at risk of developing a neurological disorder using the aforementioned assays.
Resumen de: US20260115323A1
The present invention provides a multiomics approach, which integrate single-cell RNA-sequencing (scRNA-seq) and spatiotemporal transcriptomics (ST) offering potential for dissecting transcriptional networks and revealing cell-cell interactions involved in biomolecular pathomechanisms. The present invention also provides a multimodal approach combining high-throughput scRNA-seq and ST to elucidate XLRS-specific transcriptomic signatures in two XLRS-like models with retinal splitting phenotypes, including genetically engineered (Rs1emR209C) mice and patient-derived retinal organoids harboring the same patient-specific p.R209C mutation. Through multiomics transcriptomic analysis, the endoplasmic reticulum (ER) stress/eIF2 signaling, mTOR pathway, and the regulation of eIF4 and p70S6K pathways as chronically enriched and highly conserved disease pathways between two XLRS-like models are identified. Western blots and proteomics analysis validated the occurrence of unfolded protein responses, chronic eIF2α signaling activation, and chronic ER stress-induced apoptosis. Furthermore, therapeutic targeting of the chronic ER stress/eIF2α pathway activation synergistically enhanced the efficacy of AAV mediated RS1 gene delivery, ultimately improving bipolar cell integrity, postsynaptic transmission, disorganized retinal architecture and electrophysiological responses. Collectively, the complex transcriptomic signatures obtained from Rs1emR209C mice and patient-derived retinal organoid
Resumen de: US20260115235A1
0000 It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
Resumen de: WO2026090347A1
Devices and systems for detecting and quantifying one or more targeted analytes within a biofluid (such as urine) are provided. Such devices and systems can be affixed to or embedded in a garment such as a diaper and are autonomous, noninvasive, and provide quick and accurate results. Methods for using such devices and systems to detect and/or quantify one or more targeted analytes are also provided.
Resumen de: US20260118363A1
An application of GluN2A and an NMDA receptor containing GluN2A as targets in screening antidepressant drugs, which may achieve rapid and low-cost screening of antidepressant drugs. Specifically, provided is a use of GluN2A, a binding fragment thereof or an NMDA receptor containing GluN2A in screening antidepressant drugs or in the preparation of a reagent for screening antidepressant drugs. Also provided are a method and apparatus for screening antidepressant drugs, and a kit.
Resumen de: US20260118350A1
The present invention relates to novel compounds capable of localized fluorescent signal amplification by peroxidase, a method for preparing them, and their uses as fluorescent probes. The compounds according to the present invention serve as new fluorescent amplification probes utilizing peroxidase, enabling the generation of a localized labeling pattern at the target site. Through this, they provide super-resolution protein localization information and allow the visualization of interactions between various organelles. Furthermore, they can provide localized and stable fluorescent signals in CLEM and super-resolution imaging and enable selective fluorescent labeling under fixed conditions, making them highly applicable in future proteomics and live-cell imaging.
Resumen de: US20260118346A1
Provided herein are methods of determining a cognitive status of a test subject. In some embodiments, the methods include passing a test subject data set through a model that relates test subject data sets to cognitive status of the test subjects in which the model was created using reference subject data sets produced by determining three or more features from samples obtained from the reference subjects using at least a thioflavin T (ThT) assay, a dynamic light scattering (DLS) assay, and a neurotoxicity assay. In some embodiments, the methods also include outputting from the model a classification of the test subject as having a Parkinson's disease (PD) status of PD-NC (normal cognition) or PD-CI (cognitive impairment). Related systems, computer readable media, and additional methods are also provided.
Resumen de: US20260117174A1
An object of the present invention is to provide a production method and a culture method of a three-dimensional cell culture containing human-derived neurons, human-derived astrocytes, and human-derived microglia capable of mimicking human brain functions; a three-dimensional cell culture containing human-derived neurons, human-derived astrocytes, and human-derived microglia capable of mimicking human brain functions; and an evaluation method of a test substance using the three-dimensional cell culture. According to the present invention, there is provided a production method of a three-dimensional cell culture, the production method including a step of adding, prior to co-culture of cells, human-derived astrocytes, human-derived neurons, and human-derived microglia to a culture vessel, and a step of co-culturing the astrocytes, the neurons, and the microglia in the culture vessel, in which a proportion of the astrocytes among all cells added to the culture vessel is 30% or more.
Resumen de: US20260118323A1
A method for determining multi-characteristic components of ASDZW is provided. By optimizing the gradient elution program of high performance liquid chromatography (HPLC), strictly controlling the initial mobile phase ratio of the gradient elution program, cooperating with the selections of the chromatographic column and the mobile phase, the invention finally realizes the simultaneous, rapid and comprehensive determination of six characteristic components in ASDZW under the condition of a single wavelength; specifically, the six characteristic components are polygalaxanthone III, 3,6′-disinapoyl sucrose, ginseng saponin Rb1, β-asarone, dehydrotumulosic acid, and pachymic acid. The whole detection process is a single wavelength detection with high detection efficiency and short analysis time, and the detection limits of the six components are lower than 0.008 μg/mL, meaning this method has high sensitivity, good specificity, accurate results, and good reproducibility.
Resumen de: US20260118304A1
This invention introduces an advanced odor detection and classification system that integrates optical and conductive sensors with artificial intelligence for precise, real-time identification of odor profiles across diverse fields. The system employs a colorimetric sensor to capture CIELAB values and a conductive sensor to measure voltage, with data processed through a Neural Network model. This model is trained on an extensive dataset to recognize and predict odors, adapting to variations in odor intensity for enhanced accuracy. Designed for high selectivity, stability, and resilience to environmental factors, the system is ideal for applications in medical diagnostics, food quality control, environmental monitoring, and industrial safety.
Resumen de: EP4733761A1
0001 A simple and rapid method is provided for screening proteins associated with neurodegenerative diseases or compounds useful for the treatment or prevention of neurodegenerative diseases. The method uses a probe comprising a polypeptide comprising a dipeptide repeat sequence consisting of repeating units selected from the group consisting of proline-arginine, glycine-arginine, proline-alanine, glycine-alanine, and glycine-proline, and an environment-sensitive fluorophore covalently linked thereto.
Resumen de: EP4733767A2
A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample.
Resumen de: EP4733313A2
0001 Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.
Resumen de: US20260110682A1
0000 Methods for identifying agents or manipulations that modulate copper (Cu) dyshomeostasis in an Mblac1- or swip-10-dependent manner, and for identifying agents that support Cu-dependent neuronal health in a subject are provided.
Resumen de: US20260110699A1
0000 A method for detection or monitoring status of traumatic brain injury (TBI) and/or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP/FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP/FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB/HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.
Resumen de: WO2026084043A1
The present disclosure provides a technique relating to mild cognitive impairment detection using a skin blotting sample. In this disclosure, the mild cognitive impairment detection uses a mild cognitive impairment detection marker containing at least one selected from the group consisting of Aβ - (39 + 37 + 36)/ALB, Aβ - (39 + 37)/ALB, and Aβ - (37 + 36)/ALB as a detection index.
Resumen de: WO2026085187A1
Described herein are multiplex single molecule assays for ultrasensitive detection of biomolecules, based on an ultrasensitive multiplex digital ELISA platform that substantially reduces cross-reactivity, and methods of use thereof.
Resumen de: US20260109740A1
The disclosure provides, in various embodiments, polynucleotides comprising a polyamine-responsive element and a reporter protein coding sequence encoding a reporter protein, wherein interaction between a polyamine and the polyamine-responsive element modulates expression of the reporter protein. The disclosure also provides, in various embodiments, vectors cells, and kits comprising the polynucleotides, methods of reporting an intracellular polyamine, and methods of detecting and/or reporting an intracellular polyamine analog.
Resumen de: WO2026084162A1
The present invention relates to a method for controlling the length of amyloid fibrils through a pressurized cutting process. Specifically, according to the present invention, long amyloid fibrils having a relatively long length can be uniformly cut into a desired specific length, and thus fibrils having a predetermined length can be produced precisely and reproducibly, thereby enabling cytotoxicity analysis according to the length of amyloid fibrils in neurodegenerative disease research. In addition, amyloid fibrils according to the present invention consistently maintain electrical properties, mechanical properties, and chemical reactivity due to the uniform and consistent length thereof, and thus may be suitable for commercial applications. In addition, since the pressurized cutting process of the present invention is relatively simple and economical, the commercial potential of various products and services using amyloid fibrils can be increased. Therefore, the pressurized cutting process is highly likely to be used in various technical fields such as neurodegenerative disease research, biosensors, filtration systems, nano-electronic devices, nanoparticles for drug screening, and bioadhesives.
Resumen de: WO2026085157A1
Arrhythmogenic cardiomyopathy (ACM) is a familial heart disease characterized by progressive myocardial fibrofatty infiltration. Compositions in the treatment of fibrofatty accumulation and its pathogenesis in ACM include activators of glycosphingolipid (GSL) glycosyltransferase, β-1,4-galactosyltransferase- V (β-1,4-GalT-V).
Nº publicación: WO2026083399A1 23/04/2026
Solicitante:
B G NEGEV TECH AND APPLICATIONS LTD [IL]
NAT INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD [IL]
UNIV DUKE [US]
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD.
NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
DUKE UNIVERSITY
Resumen de: WO2026083399A1
The present invention is directed to a conjugate including: (i) an antigen-binding polypeptide having a specific binding affinity to prostate specific membrane antigen (PSMA); and (ii) a benzylguanidine prosthetic group including a radionuclide, wherein (i) and (ii) are covalently bound. Further provided are a composition including the conjugate, and use of same, such as in a theranostic method.
BOPI
Sede Electrónica
